japans-shionogi-inks-14-billion-us-acquisition

Japan's Shionogi inks $1.4 billion US acquisition

The prescription drug firm buys specialised US company Sciele in the fourth Japanese outbound pharmaceutical deal in less than a year.
Japanese prescription drug firm Shionogi announced yesterday it will buy US-based Sciele Pharma for a firm value of $1.4 billion to gain distribution in the US.

Shionogi will pay $31 per share for all of ScieleÆs outstanding shares, translating into an equity value of $1.099 billion. The price is a 57% premium to Nasdaq-listed ScieleÆs six-month share price up to Friday, August 29, and a 61% premium to ScieleÆs closing price on Friday. Shionogi will also redeem $325 million of senior convertible notes on the books of Sciele, taking the Japanese company's total outlay to $1.42 billion.

Goldman Sachs was the financial adviser to Shionogi, while Davis Polk provided legal advice. Sciele used...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222